Search research articles
Contact Us
Filters
Showing results (11-20 of 57) with videos related to
Page
of 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
August 28, 2016
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience
M V Bluthgen, C Boutros, F Fayard, et al.
Revue Des Maladies Respiratoires
|
June 22, 2005
[Pneumoperitoneum and pneumomediastinum complicating non-invasive ventilation]
D Planchard, M Verdaguer, V Levrat, et al.
British Journal of Cancer
|
October 6, 2011
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer
A Lecharpentier, P Vielh, P Perez-Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2015
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D Planchard, Y Loriot, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 19, 2021
Small cell lung cancer: a slightly less orphan disease after immunotherapy
J Remon, M Aldea, B Besse, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|
June 5, 2001
[Simultaneous occlusion of the abdominal aorta and both internal carotid arteries as the presenting symptoms of left atrial myxoma]
L Corneloup, D Planchard, C Demarque, et al.
ESMO Open
|
January 28, 2026
Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison
D Planchard, J Mazières, J M Grouin, et al.
ESMO Open
|
November 14, 2022
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
R Dziadziuszko, S Peters, T Ruf, et al.
ESMO Open
|
October 10, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Y Li, H Zeng, C Qi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2014
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution
J Raphael, G Le Teuff, A Hollebecque, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 57) with videos related to
Sort By:
Page
of 6
Lung Cancer (Amsterdam, Netherlands)
|
August 28, 2016
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience
M V Bluthgen, C Boutros, F Fayard, et al.
Revue Des Maladies Respiratoires
|
June 22, 2005
[Pneumoperitoneum and pneumomediastinum complicating non-invasive ventilation]
D Planchard, M Verdaguer, V Levrat, et al.
British Journal of Cancer
|
October 6, 2011
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer
A Lecharpentier, P Vielh, P Perez-Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2015
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D Planchard, Y Loriot, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 19, 2021
Small cell lung cancer: a slightly less orphan disease after immunotherapy
J Remon, M Aldea, B Besse, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|
June 5, 2001
[Simultaneous occlusion of the abdominal aorta and both internal carotid arteries as the presenting symptoms of left atrial myxoma]
L Corneloup, D Planchard, C Demarque, et al.
ESMO Open
|
January 28, 2026
Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison
D Planchard, J Mazières, J M Grouin, et al.
ESMO Open
|
November 14, 2022
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
R Dziadziuszko, S Peters, T Ruf, et al.
ESMO Open
|
October 10, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Y Li, H Zeng, C Qi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2014
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution
J Raphael, G Le Teuff, A Hollebecque, et al.
Page
of 6